| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.0093 | 0.9 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.9 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | -0.0057 | 0.9 |